Akebia Therapeutics (AKBA) EBITDA Margin (2017 - 2026)
Akebia Therapeutics' (AKBA) quarterly EBITDA Margin came in at 8.77% in Q1 2026, down 3234.0% year-on-year from 0.28% in Q1 2025, and up 40.91% on a QoQ basis from 14.84% in Q4 2025.
Akebia Therapeutics (AKBA) EBITDA Margin (2017 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has 10 years of EBITDA Margin data on file, last reported at 8.77% in Q1 2026.
- On a quarterly basis, EBITDA Margin fell 3234.0% year-over-year to 8.77% in Q1 2026; TTM through Mar 2026 was 2.28%, a 1419.0% increase from a year earlier, with the FY2025 full-year figure at 9.95%, up 4146.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 8.77%, up from 14.84% in the prior quarter.
- Over the last five years, EBITDA Margin for AKBA reached as high as 26.97% in Q2 2022 and fell as low as 78396.05% in Q1 2022.
- Historically, EBITDA Margin has averaged 4628.8% across 5 years, with a median of 15.96% in 2023.
- Across the five-year window, EBITDA Margin plunged 7827190 bps in 2022 and soared 7833207 bps in 2023, its largest moves.
- Year by year, EBITDA Margin stood at 8.73% in 2022, then jumped by 128 bps to 2.45% in 2023, then plunged by 1358 bps to 30.77% in 2024, then jumped by 52 bps to 14.84% in 2025, then jumped by 41 bps to 8.77% in 2026.
- Per Business Quant data, the three most recent EBITDA Margin figures were 8.77% in Q1 2026, 14.84% in Q4 2025, and 7.57% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 16.37% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 36.83% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -38.02% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 41.69% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -2.27% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 23.74% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.23% |
| 10 | Akebia Therapeutics | 325.80 Mn | 163.20 Mn | 41.25 Mn | -8.77% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.77% |
| Dec 31, 2025 | -14.84% |
| Sep 30, 2025 | 7.57% |
| Jun 30, 2025 | 22.55% |
| Mar 31, 2025 | 23.57% |
| Dec 31, 2024 | -30.77% |
| Sep 30, 2024 | -33.41% |
| Jun 30, 2024 | -19.99% |
| Mar 31, 2024 | -45.81% |
| Dec 31, 2023 | 2.45% |
| Sep 30, 2023 | -31.00% |
| Jun 30, 2023 | -15.96% |
| Mar 31, 2023 | -63.98% |
| Dec 31, 2022 | -8.73% |
| Sep 30, 2022 | -103.47% |
| Jun 30, 2022 | 26.97% |
| Mar 31, 2022 | -78,396.05% |
| Dec 31, 2021 | 42.97% |
| Sep 30, 2021 | -112.57% |
| Jun 30, 2021 | -149.95% |